Sleep hypoventilation and daytime hypercapnia in stable chronic obstructive pulmonary disease

Nils Henrik Holmedahl¹
Britt Øverland²
Ove Fondenes³
Ivar Ellingsen¹
Jon Andrew Hardie⁴

¹Glitterklinikken LHL Helse as, Hakadal, Norway; ²Lovisenberg Diakonale Hospital, ENT Department, Oslo, Norway; ³Norwegian National Centre of Excellence in Home Mechanical Ventilation, Haukeland University Hospital, Bergen, Norway; ⁴Department of Clinical Science, University of Bergen, Norway

Purpose: To explore the associations between sleep hypoventilation (SH) and daytime arterial pressures of carbon dioxide ($P_{tc}CO_2$), sleep stages, and sleep apneas/hypopneas (AHI) in subjects with chronic obstructive pulmonary disease (COPD). SH has previously been found in COPD-subjects with chronic hypercapnic respiratory failure (CHRF) using supplementary oxygen (LTOT), and has been proposed as a possible predictor for CHRF.

Patients and methods: A prospectively designed observational study in a pulmonary rehabilitation hospital of 100 (39 male) stable COPD inpatients with a mean forced expiratory volume in 1 second (FEV1) of 1.1 L (42% of predicted) and a mean age of 64 years, using polysomnography with transcutaneous measurement of carbon dioxide pressure increase ($\Delta P_{tc}CO_2$).

Results: SH as defined by the American Academy of Sleep Medicine (AASM) was found in 15 of the subjects, seven of whom used LTOT. However, six had SH despite being normocapnic during the daytime (only one on LTOT). Subjects with SH had a greater $\Delta P_{tc}CO_2$ increase from nonrapid eye movement (NREM) to rapid eye movement (REM) sleep stages compared to non-SH subjects (mean [standard deviation] between-groups difference =0.23(0.20) kPa, $P<0.0005$). Subjects with apnea/hypopnea index ≥15 (overlap, N=27) did not differ from those with COPD alone (AHI <5, N=25) in sleep $\Delta P_{tc}CO_2$ or daytime $P_{tc}CO_2$. A regression model with the variables FEV1, LTOT, and sleep maximum $\Delta P_{tc}CO_2$ explained 56% of the variance in daytime $P_{tc}CO_2$ (F(3, 94) =40.37, $P<0.001$).

Conclusion: In stable COPD, SH as defined by the AASM was found both in normocapnic, non-LTOT subjects and in hypercapnic, LTOT-using subjects. Between-sleep-stage increase in $\Delta P_{tc}CO_2$ was higher in subjects with SH. Overlap subjects did not differ from simple COPD subjects in sleep $\Delta P_{tc}CO_2$ or daytime $P_{tc}CO_2$.

Keywords: blood gas analysis, etiology, physiopathology, carbon dioxide, polysomnography

Introduction

Chronic obstructive pulmonary disease (COPD) has a high and increasing morbidity and mortality worldwide, and is estimated to be the third leading cause of death by 2020.¹ Chronic hypercapnic respiratory failure (CHRF) is associated with poor prognosis in COPD. The pathophysiological mechanisms leading to CHRF are not fully established, but sleep is of particular interest as a state of unstable respiration. Blood gas sampling during sleep is difficult, as it can interfere with sleep architecture, and only a few studies of small populations have been published. In COPD, end-tidal measurement of carbon dioxide pressure is too inaccurate to substitute for arterial pressure of carbon dioxide ($P_{tc}CO_2$),³ however, transcutaneous measurement of carbon dioxide pressure ($P_{tc}CO_2$) minimally disturbs sleep, and $P_{tc}CO_2$ is now regarded by
the American Academy of Sleep Medicine (AASM) as a surrogate for $P_{aCO_2}$.4

In normal sleep, changes in central respiratory control, muscle contractility, and lung mechanics lead to hypoventilation,5–7 with arterial pressure of carbon dioxide increasing to as much as 0.9 kPa above supine, awake values.8–10 In COPD this hypoventilation is more pronounced, especially during REM sleep, as a consequence of obstructed airflow, hyperinflation, respiratory muscle dysfunction, blunted ventilatory responses to hypercapnia and hypoxemia, ventilation/perfusion mismatch, and medications.11 Poor sleep quality is often reported, and polysomnography has shown a reduced total sleep time, disturbances in sleep architecture, and highly frequent arousals.12–15 Sleep hypoventilation was a common finding in two studies of stable, hypercapnic COPD subjects on long-term oxygen treatment (LTOT).16,17 It is unclear whether this hypoventilation was mainly the result of supplementary oxygen. In COPD, daytime $P_{aCO_2}$ correlates inversely with the forced expiratory volume in 1 second (FEV1),18 and one study reported a more severe daytime hypercapnia in subjects with coexisting COPD and obstructive sleep apnea (overlap syndrome), compared to subjects with COPD or obstructive sleep apnea alone.19 Sleep hypoventilation (SH) has recently been defined by the American Academy of Sleep Medicine as an increase of 1.3 kPa or more in $P_{aCO_2}$ during sleep, to a value exceeding 6.7 kPa for at least 10 minutes.4

Finding SH in normocapnic COPD subjects may be predictive of imminent hypercapnic respiratory failure, but to our knowledge, no studies have assessed SH in COPD subjects with normocapnia or in those with CHRF without LTOT.

The primary aim of this study was to determine whether SH is associated with daytime hypercapnia, with secondary aims to explore the impact of SH on the $P_{aCO_2}$ increase between sleep stages, and whether SH or daytime $P_{aCO_2}$ is associated with the frequency of sleep apneas/hypopneas.

**Material and methods**

**Subjects**

Study participants were all Caucasians and inpatients at the Glittreklinken Pulmonary Rehabilitation Hospital from January 2010 through June 2011. Initially, 60 subjects with $P_{aCO_2}$ <6.3 kPa and 60 with $P_{aCO_2}$ ≥6.3 kPa, all with Global initiative for Chronic Obstructive Lung Disease (GOLD)20-defined COPD, were to be included. Due to fewer hypercapnic subjects, these were oversampled by asking all to participate, whereas subjects with $P_{aCO_2}$ <6.3 kPa were selected randomly, stratifying for sex prior to participation request. In total, 166 subjects were screened for participation.

The following exclusion criteria were used: diagnosed obstructive sleep apnea (OSA), COPD exacerbation within 3 weeks prior, other serious lung comorbidity (ie, cancer, sarcoidosis, restrictive lung disease) or diseases affecting thoracic or abdominal movement, unstable angina pectoris, hypertension, diabetes mellitus, myocardial infarction within last 3 months, cerebral infarction, and addiction to drugs, alcohol, or narcotics.

All subjects used prescribed medication, but no respiratory depressant drugs were taken from 48 hours prior to first polysomnography (PSG) recording until end of study. Sixty-six of the 166 subjects declined, withdrew, or were excluded. The main reasons for decline/exclusion included fear of being unable to sleep with electrodes on head and body and technical artifacts in $P_{aCO_2}$-signal (Figure 1, further details in Supplementary material). The remaining 100 PSGs of spontaneous sleep were analyzed.

The protocol was approved by the Regional Ethics Committee in southeastern Norway.

**Measurements**

Arterial blood gas samples (PICO50, Radiometer, Copenhagen, Denmark) were collected after 10 minutes seated rest at approximately 2 pm prior to PSG recording, and analyzed within 10 minutes on a Radiometer ABL720Flex (Radiometer). At sampling, all subjects were breathing room air, with the exception of those on LTOT who used their prescribed dose of supplementary oxygen. Height, weight, and lung function tests including measurement of postbronchodilator spirometry, diffusing capacity of the lung (DLCO), and body plethysmography of total lung volumes (MasterScreen Pneumo, Jaeger-Toennies, Hoechberg, Germany) were recorded during first week at the hospital. Reference values were based on equations from the European Community for Coal and Steel.21 PSG data was recorded with Embia A10 (Medcare Flaga, Reykjavik, Iceland) and $P_{aCO_2}$ data with Tosca 500 (Radiometer, Basel, Switzerland) for two nights, the first night for acquaintance with the equipment, and

---

**Figure 1** Study population. **Abbreviation:** PSG, polysomnography.
the second night recording sleep data online to a bedside computer with Somnologica Studio Version 3.3 software (Medcare Flaga). PSGs were only recorded on weekdays, with channel setup according to the 2007 recommendations from the AASM.22 When the subject went to bed, a nurse started the recording with the subject watching TV or reading to stay awake while the signal from the Tosca probe stabilized. After approximately 30 minutes, the nurse turned off the light, this time being recorded as analysis started for the PSG. Rise time in the morning was recorded by the nurse. Subjects on LTOT used their prescribed dose of oxygen during PSG.

The \( P_{\text{\text{CO}}_2} \) data were sampled with a frequency of 10 Hertz, with mean and maximum values calculated for each epoch of 30 seconds. Unpublished data collected at Glittreklinikken prior to the study showed equivalence between changes in \( P_{\text{\text{CO}}_2} \) and \( P_{\text{\text{CO}}_2} \), but with a delay time of 54–57 seconds (see Supplementary material). Thus, \( P_{\text{\text{CO}}_2} \) data were left-shifted two epochs. For each sleep stage in the PSG, the mean of each epoch’s mean \( P_{\text{\text{CO}}_2} \) values were calculated, while the epoch with the highest value was reported as the maximum \( P_{\text{\text{CO}}_2} \).

Sleep scoring was done independently by two experienced polysomnographers. Ten PSGs were scored by another two polysomnographers to select the scorer with the best concordance (see Supplementary material). According to recommendations from the AASM,22 a hypopnea was scored when nasal pressure dropped \( \geq 30\% \) for \( \geq 10 \) seconds with \( \geq 4\% \) desaturation drop from baseline, with \( \geq 90\% \) of the event’s duration meeting the amplitude reduction criteria for hypopnea (criterion A).

### Statistical analysis

Data were assessed for normality of distribution and homogeneity of variance. Differences between groups were analyzed using Pearson chi-square test, Fisher’s exact test, Mann–Whitney U test, and Student’s \( t \)-test, differences within groups by Student’s \( t \)-test. Relationships between groups were explored by chi-square tests for independence, within groups by Spearman’s rho and multiple regressions. No violation of the assumptions of normality, linearity, multicollinearity, and homoscedasticity was found preliminary to regression analysis. Concordance was measured by Cohen’s kappa. Two-sided \( P \)-values of \( \leq 0.05 \) were considered significant, except in subgroup analyses of the SH subjects (N=15), in which two-sided \( P = 0.01 \) was applied. All analyses were performed using IBM SPSS Statistics version 19 (IBM Corporation, Armonk, NY, USA).

### Results

As shown in Table 1, the group of 24 CHRF subjects had a greater increase in carbon dioxide pressure (\( \Delta P_{\text{\text{CO}}_2} \)) during sleep compared to the normocapnic subjects, and SH by the AASM definition (an increase of 1.3 kPa in the \( P_{\text{\text{CO}}_2} \) during sleep compared with awake supine level to a value exceeding 6.7 kPa for at least 10 minutes) was more frequent.4 Likewise, they had a higher median daytime base excess (BE), a lower \( P_{\text{\text{CO}}_2} \), more frequent LTOT, and they were older and over-represented by females. However, no differences were found in total sleep time (TST), sleep stages as percent of TST, awakenings, arousals, apneas, or hypopneas (a table of sleep parameters according to age and compared to normal is provided in the Supplementary material).

Oddly, no difference was found in body mass index (BMI); the mean BMI was 25 kg/m\(^2\), and only 13 were obese (BMI \( \geq 30 \) kg/m\(^2\)), whereas 26 were underweight (BMI <21 kg/m\(^2\)). As would be expected, the CHRF group had more severely obstructed airways with hyperinflation and impaired gas exchange, a shorter 6-minute walking distance (6MWD), higher dyspnea scores (modified medical research council questionnaire, COPD assessment test), and a higher BMI/obstruction/dyspnea/exercise capacity (BODE)-index.

The group of 15 SH subjects had a higher median daytime \( P_{\text{\text{CO}}_2} \), and LTOT was more frequent compared to the non-SH group (Table 1); likewise, median BE was higher. No differences were found between the SH and non-SH groups in other medication, sex, age, BMI, smoking habit, spirometry, or sleep parameters mentioned above.

On average, the 15 SH subjects were severely obstructed, with a median (interquartile range [IQR]) \( FEV_1 =0.80 \) (0.84) liters. Interestingly, however, six of the 15 SH-subjects were daytime normocapnic, with a median (IQR) \( P_{\text{\text{CO}}_2} \) of 5.00 (0.51) kPa, and only 1 used LTOT; this subgroup had a higher \( FEV_1 \) compared to the group of nine hypercapnic subjects (median [IQR] 1.45 (0.81) liters versus 0.63 (0.26) liters, \( P=0.002 \)). However, BMI and sleep apneas/hypopneas (AHI) did not differ between the normocapnic and hypercapnic SH-subjects.

As illustrated in Figure 2, the median of mean \( \Delta P_{\text{\text{CO}}_2} \) showed an increasing trend with deeper NREM sleep, and with the highest values in REM sleep, both in the non-SH group and in the SH group. A mean increase (standard deviation [SD]) from NREM to REM of 0.20 (0.16) kPa (\( P<0.001 \)) was found in the non-SH group, whereas this increase was 0.46 (0.28) kPa (\( P<0.001 \)) in the SH group, with the mean difference between the groups being 0.23 (0.20) kPa, (\( P<0.0005 \)). The pattern of gradual increase
Table 1 Differences between subjects with and without CHR and subjects with and without SH, values as median (interquartile range), N=100

|                      | Normocapnic N=76* | CHR N=24   | P       | No SH N=85 | SH N=15 | P       |
|----------------------|--------------------|------------|---------|------------|---------|---------|
| Demographic data     |                    |            |         |            |         |         |
| Sex, female          | 41 (54)*           | 20 (83)*   | 0.010   | 49 (58)*   | 12 (80)* | 0.102   |
| Age, years           | 64 (11)            | 68 (15)    | 0.032   | 65 (11)    | 64 (15)  | 0.854   |
| BMI, kg/m²           | 25.5 (6.99)        | 22.9 (9.06)| 0.199   | 24.8 (6.67)| 27.1 (11.3)| 0.916 |
| Smokëng habit        |                    |            |         |            |         |         |
| Pack years           | 34 (23)            | 25 (18)    | 0.068   | 32 (22)    | 31 (26)  | 0.783   |
| Current smoker       | 14 (18)*           | 2 (8)*     | 0.345   | 14 (17)*   | 2 (13)*  | 0.679   |
| Spirometry           |                    |            |         |            |         |         |
| FVC, % of pred'h     | 79.5 (24.3)        | 57.0 (21.0)| 0.000   | 73.5 (25)  | 67.0 (31.0)| 0.841 |
| FEV₁, % pred         | 43.0 (24.8)        | 25.0 (11.0)| 0.000   | 40.0 (24.0)| 34.0 (27.0)| 0.296 |
| FEV₁/FVC, ratio      | 0.46 (0.12)        | 0.37 (0.09)| 0.000   | 0.44 (0.14)| 0.40 (0.18)| 0.185 |
| DLCO, mmol/min/kPa'  | 3.59 (2.45)        | 2.44 (1.39)| 0.000   | 3.34 (2.20)| 2.89 (1.64)| 0.385 |
| RV/TLC, ratio        | 0.57 (0.11)        | 0.72 (0.12)| 0.000   | 0.60 (0.16)| 0.65 (0.22)| 0.297 |
| Medication           |                    |            |         |            |         |         |
| LTOT                 | 3 (4)*             | 12 (50)*   | 0.000   | 8 (9)*     | 7 (47)*  | 0.001   |
| SABA/LABA            | 71 (93)*           | 24 (100)*  | 0.333   | 80 (94)*   | 15 (100)*| 1.00    |
| Theophylline         | 3 (4)*             | 1 (4)*     | 1.00    | 4 (5)*     | 0 (0)*   | 1.00    |
| Steroid po           | 2 (3)*             | 3 (13)*    | 0.088   | 5 (6)*     | 0 (0)*   | 1.00    |
| Clinical data        |                    |            |         |            |         |         |
| CAT, score           | 17.0 (6.0)         | 21.0 (6.0)  | 0.004   | 18.0 (7.0)| 18.5 (7.0)| 0.593 |
| MMRC, score          | 2.0 (1.0)          | 3.0 (2.0)  | 0.000   | 2.0 (1.0)| 2.0 (2.0)| 0.561 |
| 6MWD, meter'         | 468 (173)          | 293 (110)  | 0.000   | 438 (186)  | 370 (203)| 0.419 |
| BODE index'          | 3.0 (3.0)          | 6.0 (2.0)  | 0.000   | 3.0 (3.0)| 6.0 (5.0)| 0.122 |
| Laboratory data      |                    |            |         |            |         |         |
| P O₂, kPa'           | 9.33 (1.47)        | 8.23 (1.84)| 0.010   | 9.13 (1.64)| 9.88 (2.28)| 0.166 |
| P CO₂, kPa'          | 5.14 (0.76)        | 6.83 (0.68)| –      | 5.33 (0.945)| 6.67 (2.09)| 0.010 |
| BE'                  | 0.85 (1.91)        | 6.44 (3.79)| 0.000   | 1.56 (2.86)| 4.36 (5.94)| 0.019 |
| CHR                  | –                  | –          | –       | 15 (18)*   | 9 (60)*  | 0.001 |
| Sleep time and awakenings |                |            |         |            |         |         |
| TST, min             | 352 (76)           | 337 (112)  | 0.218   | 348 (77)  | 354 (92) | 0.369   |
| REM% TST             | 21.9 (7.2)         | 20.5 (10.7)| 0.366   | 21.5 (7.8)| 22.1 (10.4)| 0.916 |
| WASO, min            | 46 (43)            | 53 (109)   | 0.468   | 50 (70)   | 39 (32)  | 0.265   |
| Awake                | 24 (16)            | 24 (25)    | 0.904   | 24 (17)   | 21 (19)  | 0.245   |
| Sleep arousals       |                    |            |         |            |         |         |
| TAI                  | 16.7 (9.4)         | 20.2 (15.7)| 0.116   | 17.3 (11.0)| 14.4 (13.5)| 0.466 |
| AAI                  | 1.3 (2.7)          | 1.6 (4.0)  | 0.862   | 1.30 (3.00)| 1.80 (3.60)| 0.888 |
| HAI                  | 2.8 (3.5)          | 2.0 (3.2)  | 0.183   | 2.60 (3.90)| 2.60 (3.30)| 0.714 |
| Sleep apneas/hypopneas|                |            |         |            |         |         |
| AHI                  | 9.2 (10.5)         | 9.6 (13.5) | 0.589   | 9.0 (10.4) | 9.9 (14.0) | 0.996 |
| AHI ≥15              | 20 (26)*           | 7 (29)*    | 0.784   | 23 (27)*  | 4 (27)*  | 1.00    |
with deeper sleep was not found for the median of maximum $\Delta P_{\text{CO}_2}$ (Figure 2), especially as the values in N3 sleep were lower compared to N2. In subjects without SH the N2–N3 mean $\Delta P_{\text{CO}_2}$ decrease (SD) was $-0.13$ (0.16) kPa ($P<0.001$), whereas the SH group had a mean decrease of $-0.36$ (0.41) kPa ($P=0.005$); the mean difference between the groups was $0.35$ (0.31) kPa ($P=0.002$).

With an AHI cutoff at 15/hour, concordance between the two controllers and the chosen polysomnographist was good (Kappa = 1.00 between all three scorers, N=10, P=0.002). Despite exclusion of subjects with diagnosed OSA prior to study, only 25 subjects had AHI <5/hour, whereas 27 had AHI ≥15/hour; the latter chosen to define overlap syndrome as no record of daytime sleepiness was available, while COPD alone was defined by AHI <5/hour. Central and mixed apneas were found in 28 and 27 subjects, respectively, 4 having central apnea/hypopnea index ≥1/hour (highest value 4.4/hour), and 5 having mixed apnea/hypopnea index ≥1/hour (highest value 14.1/hour). Subjects with central and mixed apneas were included for overlap analysis (Table 2). As expected, the 27 overlap subjects had a significantly lower minimum $S_2O_2$ compared to the 25 COPD subjects, both in REM and in NREM sleep. Notably, however, the overlap subjects did not differ from those with COPD in sleep $\Delta P_{\text{CO}_2}$ or daytime $P_{\text{aCO}_2}$ (Table 2), nor in the frequency of SH (15% in COPD versus 16% in the overlap group, $P=1.00$).

Finally, as sleep hypoventilation by various definitions previously has been found in severe COPD with CHRF and LTOT, a hierarchical multiple regression was performed to assess whether the maximum $P_{\text{aCO}_2}$ increase during sleep (sleep max $\Delta P_{\text{aCO}_2}$) independently predicts daytime $P_{\text{aCO}_2}$ when controlling for COPD severity (FEV$_1$) and the use of LTOT. FEV$_1$ (liters) and LTOT (yes/no) were entered at Step 1, explaining 52% of the variance in daytime $P_{\text{aCO}_2}$. After entry of sleep max $\Delta P_{\text{aCO}_2}$ (kPa) at Step 2, the total variance explained by the model was 56%, $F(3, 94) = 40.37$, $P<0.001$. Thus, sleep max $\Delta P_{\text{aCO}_2}$ explained an additional 4% of the variance in daytime $P_{\text{aCO}_2}$ after controlling for LTOT and FEV$_1$. R square change = 0.043, F change (1, 94) = 9.24, $P=0.003$. In the full model, FEV$_1$ recorded the highest beta value ($-0.44$, $P<0.001$) over LTOT (0.39, $P<0.001$) and sleep max $\Delta P_{\text{aCO}_2}$ (0.22, $P=0.003$).

**Discussion**

As previously shown by others, we find SH to be common in stable COPD subjects with CHRF using LTOT. However, the novelty in this study is that SH is also found in COPD...
with CHRF without LTOT, and even in some normocapnic, non-LTOT subjects. We also find the mean $P_aCO_2$ increasing with depth of sleep, the between-sleep-stage differences being greater in subjects with SH. Finally, overlap subjects in this study do not differ from COPD subjects in SH or in daytime $P_aCO_2$.

O’Donoghue et al found SH in 43% of 54 stable COPD subjects with CHRF, all using LTOT, when defining

Table 2 Blood gases in COPD and overlap subjects, as median (interquartile range), N=52

|                | COPD AHI $< 5$ | COPD AHI $\geq 15$ | P-value |
|----------------|----------------|--------------------|---------|
| Sleep          |                |                    |         |
| Mean $\Delta P_aCO_2$, kPa | 0.34 (0.43)   | 0.54 (0.29)   | 0.117   |
| Max $\Delta P_aCO_2$, kPa | 0.76 (0.56)   | 0.94 (0.50)   | 0.101   |
| REM max $\Delta P_aCO_2$, kPa | 0.86 (0.51)   | 1.18 (0.69) | 0.210   |
| NREM max $\Delta P_aCO_2$, kPa | 0.71 (0.59)   | 0.89 (0.49) | 0.117   |
| REM min $S_O_2$, % | 87.0 (7.7)     | 78.0 (10.0)   | 0.000   |
| NREM min $S_O_2$, % | 88.5 (5.6)     | 83.0 (11.2)   | 0.001   |
| Awake          |                |                    |         |
| $P_{O_2}$, kPa | 9.51 (1.92)   | 9.11 (1.92)   | 0.059   |
| $P_{CO_2}$, kPa | 5.36 (2.12)   | 5.38 (1.43)  | 0.880   |
| $S_O_2$, %    | 96.2 (3.2)    | 95.3 (3.4)    | 0.251   |

Notes: Prevalence of overlap could not be calculated as data on daytime sleepiness was not available. *N=24 in COPD group; one missing from $S_O_2$ and $P_{CO_2}$ due to technical problem with analysis.

Abbreviations: AHI, apnea/hypopnea Index; Max $\Delta P_aCO_2$, maximum increase in transcutaneous carbon dioxide pressure from supine, awake rest; Mean $\Delta P_aCO_2$, mean increase in transcutaneous carbon dioxide pressure from supine, awake rest; min $S_O_2$, minimum oxygen saturation measured by pulse oximeter; NREM, nonrapid eye movement sleep; REM, rapid eye movement sleep; $P_{CO_2}$, arterial pressure of carbon dioxide; $P_{O_2}$, arterial pressure of oxygen at 2:00 pm prior to sleep; $S_O_2$, arterial oxygen saturation; COPD, chronic obstructive pulmonary disease.

CHRF as daytime $P_{CO_2} > 6.12$ kPa and SH as a $\Delta P_aCO_2$ increase of $\geq 1.33$ kPa for $\geq 20\%$ of total sleep time. Similarly, Tarrega et al studied stable, hypercapnic COPD subjects on LTOT and found nocturnal hypoventilation (NHV) in 21% of their 80 subjects, defining NHV as an increase in $P_{CO_2} > 1.33$ kPa in any nocturnal blood gas sample as compared to the awake levels. Using the AASM definition, we find SH in 15% of our 100 subjects, and in seven of the 15 (47%) subjects on LTOT. Hence, this study supports O’Donoghue et al and Tarrega et al in the notion of SH being commonly found in COPD with CHRF using LTOT. Finding SH in three subjects with CHRF not using LTOT indicates that SH is associated with daytime $P_{CO_2}$ independent of LTOT. However, CHRF is not necessary either, as SH was also found in five normocapnic, non-LTOT subjects.

Figure 2 illustrates the mean $P_aCO_2$ increase with sleep stages, and the greater between-stages increase in subjects with SH versus without SH, supporting the notion that SH in COPD primarily is the consequence of a failing respiratory pump. As arterial $CO_2$ increases due to hypoventilation, the brains’ extracellular fluid bicarbonate builds up, blunting the central ventilatory drive, which in turn will lead to further elevation of $CO_2$.

In patients without COPD this vicious circle is broken by an arousal when $P_{CO_2}$ reaches 7.3–8.7 kPa. As changes in $P_{CO_2}$ are too sluggish in comparison to $P_aCO_2$ and in lack of a control group, this study did not provide data comparable to an arousal threshold. However, considering normal sleep maximum $\Delta CO_2$ is in the range of 0.3–0.9 kPa, our findings of maximum $\Delta P_aCO_2$ values of 1.2–1.8 kPa (Figure 2) suggests that COPD subjects with
SH have elevated CO₂ thresholds. With the increased levels of ∆P₂CO₂ and BE in subjects with SH, an elevated arousal threshold would be expected, hence unchanged frequencies of arousals and awakenings. Indeed, we find no significant differences in arousals, number of awakenings, or minutes of REM sleep percentage of TST between subjects with or without SH (Table 1). The lowest NREM ∆P₂CO₂ values recorded in stage N3 both in SH and non-SH subjects (Figure 2) is in line with the normal hypercapnic ventilatory response described by Douglas et al.²⁵

The overlap subjects do not differ from those with COPD alone in the frequency of SH, in sleep CO₂-increase or in daytime P₄CO₂ (Table 2), neither are there significant differences in AHI between subjects with SH versus without SH (Table 1). This can be explained by the heterogeneity of COPD, as both the lungs (gas exchange system) and the respiratory pump (ventilatory system) are affected in various degrees of severity. Frequent apneas/hypopneas are not likely to result in sleep hypercapnia in patients with well-functioning respiratory pumps, as the retained CO₂ following an apnea/hypopnea will be exhaled during the next few breaths. When scoring PSG in severely hyperinflated COPD patients, however, desaturation events resulting from a failing diaphragm can be classified as hypopneas or apneas, thus contributing to the AHI, even though there is no obstruction of the upper airways (as in OSA). In this case, one would expect to find AHI correlated to sleep CO₂ increase. Hence, severe COPD with frequent apneas/hypopneas will be classified as overlap syndrome regardless of the etiology of the desaturation events.

Contrary to the findings of Resta et al.,¹⁹ we did not find a significant difference in daytime P₄CO₂ in the overlap group as compared to the COPD group (Table 2). A main anthropometric difference between the study populations is body weight, as Resta et al reported a mean BMI of 36 kg/m² in the overlap versus 31 kg/m² in the COPD group, while our subjects had a median BMI of 25 kg/m² with no significant differences between overlap and COPD subjects. In a multiple regression model, Resta et al found the best predictors of P₄CO₂ in overlap subjects to be P₄O₂, FEV₁, and weight, O’Donoghue et al found the severity of SH in COPD subjects best predicted by a combination of baseline P₄CO₂, BMI, and percent REM sleep,¹⁷ and Tarrega et al found NHV related to BMI.¹⁶ Obesity might therefore explain the discrepancy between the findings of Resta et al and our findings.¹⁹

The variables FEV₁, use of LTOT, and sleep maximum ∆P₆CO₂ explain 56% of the variance in daytime P₄CO₂. A low FEV₁ can indicate poor function of the respiratory pump (chronic obstruction leading to hyperinflation); LTOT is known to affect the central respiratory drive to breathe,²⁶ and increased sleep ∆P₆CO₂ can indicate a blunted respiratory drive as a consequence of the failing respiratory pump. However, the intriguing subgroup of five normocapnic, non-LTOT SH subjects does not fit in the picture, as they were not obese, nor severely obstructive or hyperinflated, and they had a median AHI of only 12.8/hour. Thus, their respiratory pump should have sufficient reserves to expel CO₂ even during REM sleep.

To our knowledge, there are no previously published studies with PSG and P₄CO₂ data from COPD subjects including as many as 100 subjects. This study has its limitations, however. First, as previous studies indicate the prevalence of OSA being the same in COPD as in the normal population,²⁷ the study protocol did not include collection of daytime sleepiness data. Hence, the diagnosis of overlap syndrome based exclusively on the AHI is admittedly uncertain, and prevalence could not be analyzed. However, as OSA is defined either by AHI ≥5 and daytime sleepiness symptoms or AHI ≥15 in asymptomatic subjects,²⁸ we chose the latter to define overlap; the most conservative criterion would include only certain OSA subjects in this group, whereas AHI <5 was chosen to define subjects with COPD alone, thus reducing the risk of masking any differences between overlap and COPD groups.

Second, we do not regard the demographic profile in this study as representative for the entire COPD population in Norway, as a selection bias can be present for several reasons, including the referral/selection for lung rehabilitation, the oversampling of subjects with P₄CO₂ ≥6.3 kPa, and subjects declining to participate. As the study population had a somewhat high BODE index of 4, indicating a 4-year mortality of about 32%,²⁹ the results presented does not reflect the status of the entire COPD population, and the prevalence of SH is undoubtedly lower in patients with mild COPD.

Third, as arterial blood gas samples from the subjects using LTOT were collected when using their prescribed oxygen flow, the PO₂ and PCO₂ referred in Table 1 do not reflect the untreated values of the study population. However, as all subjects on LTOT were stable and adapted to their supplementary oxygen, blood gases measured reflects their habitual status.

**Conclusion**

Sleep hypventilation as defined by the AASM is frequently found in subjects with severe COPD and CHRF using supplementary oxygen. The novelty of this study is the finding of SH
also in CHRF without LTOT, and even in some normocapnic, non-LTOT subjects with only moderate COPD. The carbon dioxide pressure increases with deeper sleep, with differences between sleep stages being greater in subjects with SH than those without SH. Subjects with AHI ≥15/hour (overlap) do not differ from those with AHI < 5 (COPD alone) in SH, sleep ΔP_{\text{a}}{CO}_2 or in daytime P_{\text{a}}{CO}_2. A regression model with the predictors FEV₁, LTOT, and sleep maximum ΔP_{\text{a}}{CO}_2 explains half of the variance in daytime P_{\text{a}}{CO}_2.

SH is currently used in clinical practice at some centers as an independent indicator for the initiation of noninvasive positive pressure ventilation in COPD, and correction of nocturnal P_{\text{a}}{CO}_2 to normocapnic values has shown to improve lung function and may improve survival. To the best of our knowledge, however, no case-control or prospective studies have been undertaken to investigate the exact mechanisms behind SH or SH's role as a predictor for CHRF, so further research is clearly needed.

**Acknowledgments**

This work was supported by grants from the Norwegian ExtraFoundation for Health and Rehabilitation, LHL's research fund, Glittreklinikken LHL-Helse as, and the Norwegian National Centre of Excellence in Home Mechanical Ventilation. Minor grants were received from the Norwegian Lung Medicine Society/Takeda Nycomed and Major Eckbo's endowments. PSG hardware and software were provided by ResMed Norway.

**Disclosure**

This is not an industry-supported study. Nils Henrik Holmedahl has received lecture honoraria from Glaxo Smith Kline and a grant from the Norwegian Lung Medicine Society/Takeda Nycomed. Britt Øverland, Ove Fondenes, Ivar Ellingsen, and Jon Andrew Hardie report no conflicts of interest.

**References**

1. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. *Eur Respir J*. 2006;27(2):397–412.

2. Costello R, Deegan P, Fitzpatrick M, McNicholas WT. Reversible hypercapnia in chronic obstructive pulmonary disease: a distinct pattern of respiratory failure with a favorable prognosis. *Am J Med*. 1997;102(3):239–244.

3. Hatle L, Rokseth R. The arterial to end-expiratory carbon dioxide tension gradient in acute pulmonary embolism and other cardiopulmonary diseases. *Chest*. 1974;66(4):352–357.

4. Berry RB, Budhiraja R, Gottlieb DJ, et al; American Academy of Sleep Medicine. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. *J Clin Sleep Med*. 2012;8(5):597–619.

5. Meadows GE, Dunroy HM, Morrell MJ, Corfield DR. Hypercapnic cerebral vascular reactivity is decreased, in humans, during sleep compared with wakefulness. *J Appl Physiol* (1985). 2003;94(6):2197–2202.

6. Meadows GE, Kotajima F, Vazir A, et al. Overnight changes in the cerebral vascular response to isocapnic hypoxia and hypercapnia in healthy humans: protection against stroke. *Stroke*. 2005;36(11):2367–2372.

7. Douglas NI, White DP, Pickett CK, Weil JV, Zwislicz CW. Respiration during sleep in normal man. *Thorax*. 1982;37(11):840–844.

8. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. *Sleep*. 1999;22(5):667–689.

9. Birchfield RI, Sieker HO, Heyman A. Alterations in blood gases during natural sleep and narcolepsy; a correlation with the electroencephalographic stages of sleep. *Neurology*. 1958;8(2):107–112.

10. Bristow JD, Honour AJ, Pickering TG, Sleight P. Cardiovascular and respiratory changes during sleep in normal and hypertensive subjects. *Cardiovasc Res*. 1969;3(4):476–485.

11. McNicholas WT, Lee R. Obstructive sleep apnoea and COPD. *European Respiratory Monograph*. 2013(59):135–143.

12. Cormick W, Olson LG, Hansley MJ, Saunders NA. Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. *Thorax*. 1986;41(11):846–854.

13. Fleetham J, West P, Mezon B, Conway W, Roth T, Kryger M. Sleep, arousals, and oxygen desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy. *Am Rev Respir Dis*. 1982;126(3):429–433.

14. Valpior A, Lavie P, Lothaler H, Mikulic I, Burghuber OC. Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease. *Sleep Med*. 2011;12(4):367–372.

15. McSharry DG, Ryan S, Calverley P, Edwards JC, McNicholas WT. Sleep quality in chronic obstructive pulmonary disease. *Respirology*. 2012;17(7):1119–1124.

16. Tarrega J, Anton A, Guell R, et al. Predicting nocturnal hypventilation in hypercapnic chronic obstructive pulmonary disease patients undergoing long-term oxygen therapy. *Respiration*. 2011;82(1):4–9.

17. O’Donoghue FJ, Catcheside PG, Ellis EE, et al; Australian trial of Noninvasive Ventilation in Chronic Airflow Limitation investigators. Sleep hypoventilation in hypercapnic chronic obstructive pulmonary disease: prevalence and associated factors. *Eur Respir J*. 2003;21(6):977–984.

18. Saure EW, Eagan TM, Jensen RL, et al. Explained variance for blood gases in a population with COPD. *Clin Respir J*. 2012;6(2):72–80.

19. Resta O, Foschino Barbaro MP, Brindicci C, Nocerino MC, Caratuzzolo G, Carbonara M. Hypercapnia in overlap syndrome: possible determinant factors. *Sleep Breath*. 2002;6(1):11–18.

20. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global strategy for the diagnosis, treatment, and prevention of chronic obstructive pulmonary disease. Updated 2013. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed December 19, 2013.

21. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report of the working party on respiratory function in health on the basis of the standardization and lung age. *Eur Respir J Suppl*. 1993;16:5–40.

22. Iber C, Ancoli-Israel S, Chesson AL Jr, Quan SF; for the American Academy of Sleep Medicine. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. Westchester, IL: American Academy of Sleep Medicine; 2007.

23. Javaheri S, Shore NS, Rose B, Kazemi H. Compensatory hyperventilation in metabolic alkalosis. *Chest*. 1982;81(3):296–301.
24. Berthon-Jones M, Sullivan CE. Ventilation and arousal responses to hypercapnia in normal sleeping humans. *J Appl Physiol Respir Environ Exerc Physiol*. 1984;57(1):59–67.

25. Douglas NJ. Control of ventilation during sleep. *Clin Chest Med*. 1985;6(4):563–575.

26. Aubier M, Murciano D, Milic-Emili J, et al. Effects of the administration of O2 on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure. *Am Rev Respir Dis*. 1980;122(5):747–754.

27. Weitzenblum E, Chaouat A, Kessler R, Canuet M. Overlap syndrome: obstructive sleep apnea in patients with chronic obstructive pulmonary disease. *Proc Am Thorac Soc*. 2008;5(2):237–241.

28. Hauri PJ (Ed). *The International Classification of Sleep Disorders*. 2nd ed. Diagnostic and Coding Manual. Westchester 2005.

29. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med*. 2004;350(10):1005–1012.

30. Windisch W, Walterspacher S, Siemon K, Geiseler J, Sitter H; German Society for Pneumology. Guidelines for non-invasive and invasive mechanical ventilation for treatment of chronic respiratory failure. Published by the German Society for Pneumology (DGP). *Pneumologie*. 2010;64(10):640–652.

31. Windisch W, Haenel M, Storre JH, Dreher M. High-intensity non-invasive positive pressure ventilation for stable hypercapnic COPD. *Int J Med Sci*. 2009;6(2):72–76.

32. McEvoy RD, Pierce RJ, Hillman D, et al; Australian trial of non-invasive Ventilation in Chronic Airflow Limitation (AVCAL) Study Group. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. *Thorax*. 2009;64(7):561–566.
Supplementary material

Subjects
Reasons given from the 26 subjects not participating: Anxiety/fear of not being able to sleep with electrodes connected to head/body (ten subjects); not willing to discontinue sedentary medication (three subjects); fear that sleep studies would interfere with the rehabilitation program (three subjects); did not want sleep investigated (three subjects); fear of pain from blood gas sampling (two subjects). Two subjects declined because an interventional part of the project (not published) implied sleeping with supplementary oxygen or taking alcohol or zopiclone before sleep for a third polysomnography. One subject did not want to be seen with wires connected to the head, one needed to go outdoors for smoking at night and one did not give a reason.

Reasons for drop out of 17 subjects after initial consent given: Felt it impossible to sleep with wires on the body (seven subjects); exacerbation of COPD (six subjects); technical or protocol failure (two subjects); illness/disease of other cause (one subject); medication which excluded (one subject).

Twenty-three polysomnographies were excluded because of technical artifacts in transcutaneous measurement of PCO$_2$; 17 because the P$_{tc}$CO$_2$ probe periodically lost contact with skin (low P$_{tc}$CO$_2$-signal); six because the probe was compressed by pillow or hand/arm (high P$_{tc}$CO$_2$-signal).

P$_{tc}$CO$_2$ versus P$_a$CO$_2$

The correlation between P$_{tc}$CO$_2$ and P$_a$CO$_2$ has been studied in stable subjects with lung diseases, in critically ill subjects, during cardio-pulmonary exercise testing and in circulatory stable subjects; both inactive and during exercise. Conclusions varied as to whether P$_{tc}$CO$_2$ can substitute P$_a$CO$_2$. Hence, clinical data were obtained from 18 stable, supine COPD subjects with an indwelling catheter at Glitteklinikken (mean FEV$_1$(SD)=46(26)% of predicted, N=4 had P$_{tc}$CO$_2$ > 6.3 kPa). Every twentieth minute for up to six hours a pair of P$_a$CO$_2$ and P$_{tc}$CO$_2$ values were recorded. From 204 pairs, a mean difference (SD) P$_a$CO$_2$–P$_{tc}$CO$_2$ of 0.233 (0.312) kPa was found; this SD regarded as too high a variance to let the absolute values of P$_a$CO$_2$ substitute those of P$_{tc}$CO$_2$. However, the within subject mean difference (SD) P$_a$CO$_2$– P$_{tc}$CO$_2$ was 0.229 (0.186) kPa. We concluded that the within subject SD of < 0.2 kPa indicates that the changes in P$_a$CO$_2$ can substitute the changes in P$_{tc}$CO$_2$. Consequently, when studying COPD subjects with PSG and P$_{tc}$CO$_2$ we recorded the changes in P$_a$CO$_2$ during sleep, not the absolute values.

P$_{tc}$CO$_2$ delay time

To find the time delay from an alveolar change in PCO$_2$ until the first response in P$_{tc}$CO$_2$, we studied nine COPD subjects (six male) with a mean FEV$_1$(SD) of 41(20)% of predicted, and P$_{tc}$CO$_2$< 6.3 kPa. The supine subjects wore a tight fitting face mask, inlet selecting either room air or a gas mixture of 4% CO$_2$ in air. Data were collected in three phases, each lasting 200 sec: 1) stable phase breathing room air; 2) increasing phase breathing 4% CO$_2$, and 3) decreasing phase after switching back to room air. P$_{tc}$CO$_2$ was recorded every 5th second for 2 minutes, then every 10th second in each phase. Arterial blood samples were taken from an

Table S1 | Sleep parameters according to age, compared to reference populations with normal lung function, N=100

| Age groups | 46–59 years | 60–69 years | 70–82 years |
|------------|-------------|-------------|-------------|
|            | Results (Reference values*) | Results (Reference values*) | Results (Reference values*) |
|            | N=29        | N=47        | N=24        |
| Sleep summary |             |             |             |
| TST, min   | 347 (367)   | 360 (349)   | 296 (335)   |
|            | 56.7 (58.0) | 54.0 (51.5) | 56.3 (56.7) |
| Awake      | 21 (9.7)    | 27 (14.6)   | 36 (na)     |
|            | 9.1 (5.2)   | 12 (6.7)    | 30.1 (na)   |
| WASO, min  | 40 (na)     | 60 (na)     | 105 (75)    |
|            | 40 (na)     | 39 (na)     | 61 (na)     |
| SES,%      | 90 (90)     | 86 (9.1)    | 74 (82)     |
|            | 11 (7.1)    | 86 (7.9)    | 15 (na)     |
| Sleep stage percentage of total sleep time |             |             |             |
| N1         | 13 (5.2)    | 17 (4.8)    | 21 (12)     |
|            | 6.6 (4.2)   | 7.1 (3.3)   | 11.7 (na)   |
| N2         | 39 (63)     | 41 (68)     | 37 (56)     |
|            | 8.4 (17)    | 7.3 (13)    | 10 (na)     |
| N3         | 26 (8.8)    | 21 (8.7)    | 22 (13)     |
|            | 9.4 (7.3)   | 11 (7.9)    | 12 (na)     |
| REM        | 22 (23)     | 21 (19)     | 20 (19)     |
|            | 7.2 (7.5)   | 6.2 (8.5)   | 8.5 (na)    |

Notes: *Reference values according to M. Ohayon et al
*Reference values according to M. Hirschkowitz et al
Abbreviations: TST, total sleep time; Awake, number of awakenings; WASO, minutes awake after sleep onset; SES, sleep efficiency from sleep start; N1, stage N1 sleep; N2, stage N2 sleep; N3, stage N3 sleep; REM, rapid eye movement sleep; na, not available.
indwelling catheter three times during phase 1), every 5th second the first 30 sec of phase 2) and 3), then every 30th second for a total of 150 seconds. The results showed a first response time (frt) meaning time from change in alveolar PCO₂ to PₜcCO₂ > 2SD off stable phase as follows: Mean frt(SD) in increasing phase: 54(5.6) sec; Mean frt(SD) in decreasing phase: 57(15) sec. For arterial PCO₂: 13.3(5.6) sec and 11.7(2.5) sec, accordingly.

Sleep scoring
All PSG’s were initially scored by two independent, registered polysomnographists (RPSG’s) blinded to subject data except sex, age, height and weight. As the scorings from these two RPSG’s differed substantially on several sleep parameters (eg, AHI, HI, sleep stages) a random selection of 10 PSG’s were scored by another two RPSG’s who were blinded regarding the results from the first two scorers. The scorings from the initial RPSG with the best match to the last two RPSG’s were then selected for data analysis.

Results, table supplement
When compared to normal subjects, the study-subjects had twice to threefold more awakenings and N1-sleep. However, they had a normal amount of REM-sleep and about twice the percentage of slow wave (N3) sleep (table 1).

References
1. Parker SM, Gibson GJ. Evaluation of a transcutaneous carbon dioxide monitor (“TOSCA”) in adult patients in routine respiratory practice. Respir. Med. Feb 2007;101(2):261–264.
2. Senn O, Clarenbach CF, Kaplan V, Maggiorini M, Bloch KE. Monitoring carbon dioxide tension and arterial oxygen saturation by a single earlobe sensor in patients with critical illness or sleep apnea. Chest. Sep 2005;128(3):1291–1296.
3. Bolliger D, Steiner LA, Kasper J, Aziz OA, Filipovic M, Seeberger MD. The accuracy of non-invasive carbon dioxide monitoring: a clinical evaluation of two transcutaneous systems. Anaesthesia. Apr 2007;62(4):394–399.
4. Rodriguez P, Lellouche F, Aboab J, Buisson CB, Brochard L. Transcutaneous arterial carbon dioxide pressure monitoring in critically ill adult patients. Intensive Care Med. Feb 2006;32(2):309–312.
5. Storre JH, Steurer B, Kabitz HI, Dreher M, Windisch W. Transcutaneous PCO2 monitoring during initiation of noninvasive ventilation. Chest. Dec 2007;132(6):1810–1816.
6. Stege G, van den Elshout FJ, Heijdra YF, van de Ven MJ, Dekhuijzen PN, Vos PJ. Accuracy of transtabcutaneous carbon dioxide tension measurements during cardiopulmonary exercise testing. Respiration. 2009;78(2):147–153.
7. Janssens JP, Perrin E, Bennani I, de Muralt B, Titelion V, Picaud C. Is continuous transcutaneous monitoring of PCO2 (TcPCO2) over 8 h reliable in adults? Respir. Med. May 2001;95(5):331–335.
8. Janssens JP, Laszlo A, Uldry C, Titelion V, Picaud C, Michel JP. Non-invasive (transcutaneous) monitoring of PCO2 (TcPCO2) in older adults. Gerontology. May–Jun 2005;51(3):174–178.
9. Hirshkowitz M, Moore CA, Hamilton CR, 3rd, Rando KC, Karacan I. Polysomnography of adults and elderly: sleep architecture, respiration, and leg movement. J Clin Neurophysiol. Jan 1992;9(1):56–62.
10. Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep. Nov 1 2004;27(7):1255–1273.